The tulisokibart news came as MSD – known as Merck & Co in the US and Canada – reported a higher-than-expected 5% rise in ...

Kim Innes is General Manager of Teva UK. She has more than 30 years’ experience across the pharmaceutical industry. A Harvard ...

The criteria developed by UK health technology assessment (HTA) agency NICE to decide who should be referred by GPs for ...

Pathos AI has added to its pipeline of cancer drugs by licensing a bispecific antibody-drug conjugate (ADC) for solid tumours ...

Under the terms of the deal, ‌Lantheus' shareholders will get $102.50 per share in cash when the deal closes, along with the ...

Supernus Pharma and Indivior have signed an all-stock merger agreement that would establish a new company, focused on central ...

Novartis paid out $195 million in 2020 to settle a criminal claim brought by the federal government – at the time, the ...

The last mega-mergers between big pharma companies were BMS' $74 billion deal with Celgene in 2019 and the $63 billion AbbVie ...

Henry Gosebruch, pictured here during his time at Neumora, is replacing Paul Stoffels as CEO of Galapagos. Just a few months after announcing a plan to separate its drug and cell therapy businesses ...

Analysts said the ZEUS failure makes ziltivekimab a high-risk asset and increases the pressure on Novo Nordisk to carry out ...

The FDA has approved AbbVie's Decnupaz, a treatment for rare blood cancer blastic plasmacytoid dendritic cell neoplasm (BPDCN) that was one of the assets in its $10.1 billion takeover of ImmunoGen in ...

Dame Emma Walmsley has been CEO at GSK since 2017. This week has kicked off with the unexpected news that Emma Walmsley is standing down as chief executive of GSK after eight years, to be replaced by ...